相关实验视频

Updated: Feb 6, 2026

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

Published on: August 22, 2025

乳腺癌免疫治疗中的双特异抗体:机制,进展和转化挑战

Marianna Rita Brogna¹, Gerardo Ferrara², Valeria Varone²

¹Pathology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. brognamarianna@gmail.com.

Targeted oncology

|February 4, 2026

概括

双特异性抗体 (BsAbs) 提供了一种针对乳腺癌的新型免疫治疗方法,通过吸引瘤抗原和T细胞. 这些工程抗体有望克服当前治疗的局限性,特别是三阴性乳腺癌 (TNBC).

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子生物学分子生物学

背景情况:

乳腺癌仍然是死亡的重要原因,尽管现有的疗法.
免疫检查点抑制剂 (ICI) 在乳腺癌中表现出有限的疗效,主要是在三阴性乳腺癌 (TNBC) 中.
为了更广泛的乳腺癌治疗适用性,需要创新的免疫治疗策略.

研究的目的:

审查乳腺癌治疗中双特异抗体 (BsAbs) 的机制,临床前数据,临床结果和挑战.
突出BsAbs在乳腺癌中克服当前免疫治疗局限性的潜力.

主要方法:

对乳腺癌BsAbs的临床前研究和早期临床试验的审查.
对BsAb设计进步的分析,包括分子格式和工程策略.
检查TAA参与,免疫细胞招募和瘤细胞溶解机制.

主要成果:

BsAbs参与瘤相关抗原 (TAA) 和免疫效应细胞 (例如CD3+ T淋巴细胞) 诱导向瘤细胞溶解.
优化的BsAb设计改善了瘤透,药理动力学,并降低了毒性.
临床前和早期临床数据显示出显著的抗瘤活性,无论是单一治疗还是组合治疗.

结论:

BsAbs代表了乳腺癌的一种有前途的治疗方式,有可能扩大免疫治疗疗效.
需要进一步的研究来解决TAA表达变异性和细胞因子释放综合征 (CRS) 等挑战.
在瘤微环境中,BsAbs具有克服免疫抑制和免疫逃脱的变革潜力.

更多相关视频

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

相关概念视频

Translation

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Initiation of Translation

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...

Termination of Translation

Termination of Translation

The large ribosomal subunit has several important structures essential to translation. These include the peptidyl transferase center (PTC) - which is the site where the peptide bond is formed - and a large, internal, water-filled tube through which the nascent polypeptide moves. This latter structure is called the Peptide Exit Tunnel, and it begins at the PTC and spans the body of the large ribosomal subunit. During translation, as the nascent polypeptide chain is synthesized, it passes through...